PARP1 and cancer: Studies based on the role of these PARPs in the DDR in cancer cells have led to the development of PARP inhibitors as new therapeutic tools in cancer, both as adjuvant treatment potentiating chemotherapy, radiotherapy, and immunotherapy and as monotherapy exploiting cancer cell-specific defects in DNA repair, such as BRCA mutations [6,7,8,9].